the efficacy of olutasidenib in aml following venetoclax failure
Published 3 months ago • 64 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:22
responses to olutasidenib in patients with aml who have failed treatment with venetoclax
-
1:37
long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
-
1:31
five-year follow-up of olutasidenib for idh1-mutated r/r aml
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
2:44
azacitidine, venetoclax & gilteritinib in older/unfit patients with flt3-mutated aml
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml
-
9:46
venetoclax prior to allo-hct for high-risk myeloid malignancies
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
4:32
acute promyelocytic leukemia (apl) illness script video
-
1:06:04
itp: novel treatments
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:17
novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:13
efficacy of transplantation in hl
-
2:09
overview of the cll13 trial: replacing chemotherapy with venetoclax-containing regimens
-
1:01
pirtobrutinib, venetoclax, and rituximab in the treatment of r/r cll: insights from the bruin trial
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
0:47
overview of the phase iii enhance trial schema
-
3:15
overview of a phase ib study of venetoclax and obinutuzumab in cll
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:18
first-line ibrutinib and venetoclax in cll